Horizon Pharma Usa patents expiration
1. Procysbi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9925156 | HORIZON PHARMA USA | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(3 years from now) | |
| US9198882 | HORIZON PHARMA USA | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(3 years from now) | |
| US9192590 | HORIZON PHARMA USA | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(3 years from now) | |
| US9925158 | HORIZON PHARMA USA | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(3 years from now) | |
| US9925157 | HORIZON PHARMA USA | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(3 years from now) | |
|
US9198882 (Pediatric) | HORIZON PHARMA USA | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
|
US9192590 (Pediatric) | HORIZON PHARMA USA | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
| US8026284 | HORIZON PHARMA USA | Enterically coated cystamine, cysteamine and derivatives thereof |
Sep, 2027
(3 years from now) | |
|
US8026284 (Pediatric) | HORIZON PHARMA USA | Enterically coated cystamine, cysteamine and derivatives thereof |
Mar, 2028
(4 years from now) | |
| US9233077 | HORIZON PHARMA USA | Delayed release cysteamine bead formulation, and methods of making and using same |
Jun, 2034
(10 years from now) | |
| US9173851 | HORIZON PHARMA USA | Delayed release cysteamine bead formulation, and methods of making and using same |
Jun, 2034
(10 years from now) | |
|
US9233077 (Pediatric) | HORIZON PHARMA USA | Delayed release cysteamine bead formulation, and methods of making and using same |
Dec, 2034
(11 years from now) | |
|
US9173851 (Pediatric) | HORIZON PHARMA USA | Delayed release cysteamine bead formulation, and methods of making and using same |
Dec, 2034
(11 years from now) | |
| US10143665 | HORIZON PHARMA USA | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
| US10548859 | HORIZON PHARMA USA | Methods for storing Cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
| US10328037 | HORIZON PHARMA USA | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
| US10905662 | HORIZON PHARMA USA | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE* (ODE*) | Dec 22, 2024 |
| Pediatric Exclusivity (PED) | Jun 22, 2025 |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Market Authorisation Date: 14 February, 2020
Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Dosage: GRANULE, DELAYED RELEASE;ORAL
PROCYSBI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic